These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30522358)

  • 1. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
    Lawania S; Singh N; Behera D; Sharma S
    Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
    Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
    Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
    Sharma P; Singh N; Sharma S
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.
    Singh A; Singh N; Behera D; Sharma S
    Pathol Oncol Res; 2019 Oct; 25(4):1327-1340. PubMed ID: 29209987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy.
    Singh A; Singh N; Behera D; Sharma S
    Med Oncol; 2017 Apr; 34(4):64. PubMed ID: 28332164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.
    Hu W; Pan J; Zhao P; Yang G; Yang S
    Tumour Biol; 2014 Jun; 35(6):5561-7. PubMed ID: 24615519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
    Zou HZ; Zhao YQ
    Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.
    Singh A; Singh N; Behera D; Sharma S
    Mol Biol Rep; 2018 Jun; 45(3):253-261. PubMed ID: 29397516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
    Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
    Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
    Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.